JPMorgan Upgrades Kodiak Sciences on KSI-101 Potential
JPMorgan raises Kodiak Sciences rating to Overweight with $24 price target, citing reduced risk for KSI-101 drug treating eye inflammation and swelling.
/ 2 items
JPMorgan raises Kodiak Sciences rating to Overweight with $24 price target, citing reduced risk for KSI-101 drug treating eye inflammation and swelling.
Kodiak gets a "Buy" rating and $15 target. Final results for its 3 eye drugs are due 2026. Watch for rival Roche's data soon.